This new volume delves into the extensive new research on inflammatory bowel disease (IBD) and gut microbiota that has led to effective therapeutic interventions. Highlighting novel methodologies and innovative treatment approaches, the book provides a comprehensive investigation of IBD, exploring the significance of gut microbiota and investigating the fundamental role of microbial imbalances in the initiation and progression of inflammatory processes as well as the prominent therapeutic consequences of restoring microbial homeostasis. From nanoparticle-based drug delivery systems that advance the bioavailability of the medicament to the use of bio-nanosensors for early detection of disease, the book covers a broad spectrum of inventions that hold potential for revolutionizing IBD treatment. The authors look at the impact of nutraceuticals, probiotics, prebiotics, functional foods, oral siRNA-based nanomedicine, and other novel drug delivery systems on gut microbiota for the management of IBD. The book also explores the role of reactive oxygen species (ROSs), superoxide dismutases (SODs), and inflammation in association with gut microbiota and IBD.
Neeraj Mishra, PhD, is a Professor at the Amity Institute of Pharmacy, Gwalior, India. He has 20 years of teaching and research experience. A brand ambassador at Bentham Science, he has published more than 100 papers on recent concepts of novel drug delivery systems, oral delivery of synbiotics, localized drug delivery, targeted and controlled drug delivery of nanocarriers/microparticles for the treatment of breast and colon cancer, and neurodegenerative disorders. He has also written more than 15 books and 25 book chapters and has been granted several patents. He was a recipient of an Indian Council of Medical Research Senior Research Fellowship and a Distinguished Professor Award from the Indian Department of Science and Technology, National Science and Technology Management Information System, Synergizing Pharma Academic-Industry Collaboration Systems.
Sumel Ashique, MPharm, is a Research Scholar at the School of Pharmaceutical Sciences at Lovely Professional University, Punjab, India, where he is pursuing his PhD. His research area is probiotics, postbiotics, gut microbiota, and inflammatory disorders. With knowledge in drug delivery, nanotechnology, and targeted treatment strategy, he has four years of teaching experience and has published book chapters with international publishers and over 100 papers in accredited reputed journals. He has also six granted intellectual property (IP) patents from IP India and Australia. He is currently editing 13 books with Apple Academic Press, CRC Press, Taylor and Francis, and others.
Ashish Garg, PhD, is a Professor at the Guru Ramdas Khalsa Institute of Science and Technology (Pharmacy), Jabalpur, M.P., India. He has around ten years of teaching and research experience and has 80 publications in national and international journals of repute. He has authored 27 book chapters and edited several books on recent concepts of nanotechnology, novel drug delivery systems, cancer targeting, etc. Dr. Garg has been granted three international patents and has published three Indian patents. He also acts as an editorial board member and reviewer for several journals.
